My Top 5 Stocks to Buy in Early 2026

Motley Fool recommends five stock ideas for early 2026 — Amazon, Eli Lilly, Chewy, Apple and Moderna — emphasizing durable earnings and growth catalysts: Amazon’s e-commerce and AWS (AWS annual revenue run rate > $132 billion) underpin an AI-exposure play; Apple’s Apple Intelligence rollout and record services revenue support further services growth; Chewy’s Autoship now represents 84% of sales while shares trade near 26x forward earnings (down from >36x). In healthcare, Lilly benefits from tirzepatide blockbusters (Zepbound/Mounjaro) with the weight‑loss market forecast near $100 billion by decade-end, while Moderna is positioned as a recovery candidate aiming to expand its seasonal vaccine franchise from three to six products and reach cash breakeven by 2028 despite recent disappointing vaccine sales.

Analysis

Market structure: AI and cloud are the clear winners — AMZN/AWS, NVDA and AVGO benefit from secular capex into generative AI and higher-margin software services, while legacy retail (small e-tailers, some brick‑and‑mortar chains) lose pricing power as Amazon leverages automation to compress fulfillment costs. Healthcare winners are concentrated innovators with differentiated drugs (LLY) but the sector faces binary-payor outcomes that reallocate margins to manufacturers with clear clinical/price power. Cross-assets: stronger tech/AI sentiment typically steepens the yield curve (equity risk appetite up, bond demand down) and lifts volatility in skew-sensitive options markets; USD may strengthen modestly as risk appetite rebalances flows into large caps.

Risk assessment: Key tail risks are regulatory pricing/payer crackdowns on GLP-1/weight-loss drugs (LLY) and antitrust/AI governance curbs on cloud giants (AMZN) — each could inflict 20–50% drawdowns on headline valuations in 6–18 months. Immediate (days): earnings/FDA headlines; short-term (1–3 months): Q1 prints and any FDA decision on Lilly’s oral candidate; long-term (2–3 years): product adoption and margin convergence. Hidden dependencies include Autoship concentration for CHWY (84% sales) and Moderna’s revenue sensitivity to seasonal demand and successful late‑stage readouts.

Trade implications: Take directional but size‑controlled positions: overweight AMZN (2–3% portfolio) for 12–18 months tied to AWS AI monetization; tactical long LLY (1–2%) ahead of FDA decision with 20% stop; small satellite long CHWY (1%) paired vs short WMT (0.5%) to play recurring-revenue capture. For MRNA, use hedged option exposure (buy 9–12 month call spreads sized to 0.5% risk) instead of naked stock. Options: buy AAPL 12–18 month LEAP calls (delta ~0.4) to play services re-rating while funding via short near-term calls if IV rises.

Contrarian angles: Consensus overweights AI winners may underprice GLP-1 reimbursement risk — if payors impose step therapy or price caps, LLY EPS could compress >30% vs current expectations. Amazon’s AI benefit is priced for durable margin expansion; a mild slowdown in e‑commerce automation ROI would leave upside limited. Moderna’s selloff may be overdone if two mid‑late trials read out positive in 2026; a small, option‑hedged speculative position captures asymmetric upside while capping downside.

Key Decisions for Investors

• Establish a 2–3% long position in AMZN (equal‑weighted across shares and 9–12 month call LEAPs) targeting 15–25% upside over 12–18 months; set trailing stop at -25% or hedge with 6‑month puts if AWS revenue growth misses consensus.
• Initiate a 1–2% long position in LLY ahead of the imminent weight‑loss pill regulatory window (expect binary move within 30–90 days); size for risk and set hard stop at -20% or sell into a >15% pop post‑approval.
• Add a 1% long position in CHWY and short 0.5% WMT (pair trade) to play recurring Autoship strength vs general retail; exit if CHWY Autoship metric falls below 78% or same‑store sales decelerate sequentially.
• Avoid large outright MRNA equity positions; instead buy a 9–12 month call spread sized to 0.5% portfolio risk (cap downside) to capture pipeline catalysts and potential re‑rating by end of 2026.
• Rotate 3–5% of tech exposure toward AAPL LEAP calls (12–18 month, delta ~0.4) to play services/Apple Intelligence upside; finance by selling 3‑6 month covered calls on ~20% of the position if implied volatility rises >15% vs historical 12‑month average.